Catalyst Event
Amgen Inc (AMGN) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
6/3/2026, 12:00:00 AM
Presented new Phase 3 data for UPLIZNA at the EULAR 2026 Congress, showing a 0% flare rate over one year in patients with IgG4-Related Disease who continued treatment. Medium importance as positive clinical data supports market share, expected.
Korean Translation
EULAR 2026 학회에서 UPLIZNA의 새로운 3상 데이터를 발표함. 치료를 지속한 IgG4 관련 질환 환자에서 1년간 재발률 0%를 기록함. 긍정적인 임상 데이터는 시장 점유율 확대에 기여하므로 중간 중요도로 분류함, 예상됨.
Related Recent Events
Life Time Group Holdings Inc (LTH) · Earnings Release
Q2 2026 earnings release on 2026-08-04 with analyst EPS forecast of $0.43; low importance estimated due to no current market impact, expected.
8/4/2026, 12:00:00 AM
Novartis AG (NVS) · Earnings Release
Second quarter 2026 financial results for 2026-07-21; low importance estimated as the date is a routine reporting event with an expected impact of approximately 1% scheduled.
7/21/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Earnings Release
Abbott is expected to announce its Q2 2026 earnings results on July 16, 2026. This key quarterly financial update is estimated to have a moderate price impact of at least 5%, scheduled.
7/16/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Other
FDA action date (PDUFA) for supplemental applications for WELIREG in combination with KEYTRUDA for the adjuvant treatment of certain patients with renal cell carcinoma (RCC) is scheduled for June 19, 2026, scheduled.
6/19/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Other
Quarterly dividend of $0.85 per share has an ex-dividend date of June 15, 2026, scheduled.
6/15/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Other
Ex-dividend date for a quarterly cash dividend of $1.25 per share on 2026-06-12. The dividend was declared on May 26, 2026, and is payable on June 26, 2026. A price impact of approximately 1% is expected based on the dividend amount.
6/12/2026, 12:00:00 AM